XML 50 R98.htm IDEA: XBRL DOCUMENT
v3.20.1

Goodwill and Intangible Assets, Net - Goodwill Impairment Inputs (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | ---
Mar. 31, 2019 | Dec. 31, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Sep. 30, 2017 | Mar. 31, 2018 | Mar. 31, 2020 | Mar. 31, 2019 | Mar. 31, 2018
Goodwill [Line Items] |  |  |  |  |  |  |  |  |
Goodwill impairment charge |  |  |  |  |  |  | $ 2 | $ 1,797 | $ 1,738
Mckesson Europe and Rexall |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |
Goodwill impairment charge |  |  |  |  |  | $ 1,738 |  |  |
European Pharmaceutical Solutions |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |
Goodwill impairment charge | $ 1,200 |  | $ 570 |  |  |  | 0 | 1,776 | $ 1,300
European Pharmaceutical Solutions | PD |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |
Goodwill impairment, discount rate (percent) |  |  | 8.00% |  |  |  |  |  |
Goodwill impairment, terminal growth rate (percent) |  |  | 1.25% |  |  |  |  |  |
Goodwill impairment charge |  |  | $ 238 |  |  |  |  |  |
European Pharmaceutical Solutions | RP |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |
Goodwill impairment, discount rate (percent) | 10.00% |  | 8.50% |  |  |  |  |  |
Goodwill impairment, terminal growth rate (percent) | 1.25% |  | 1.25% |  |  |  |  |  |
Goodwill impairment charge | $ 465 |  | $ 251 |  |  |  |  |  |
European Pharmaceutical Solutions | PD |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |
Goodwill impairment, discount rate (percent) |  |  | 8.00% |  |  |  |  |  |
Goodwill impairment, terminal growth rate (percent) |  |  | 1.25% |  |  |  |  |  |
Goodwill impairment charge |  |  | $ 81 |  |  |  |  |  |
European Pharmaceutical Solutions | PD |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |
Goodwill impairment, discount rate (percent) | 9.00% |  |  |  |  |  |  |  |
Goodwill impairment, terminal growth rate (percent) | 1.25% |  |  |  |  |  |  |  |
Goodwill impairment charge | $ 741 |  |  |  |  |  |  |  |
European Pharmaceutical Solutions | Mckesson Europe Reporting Unit |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |
Goodwill impairment, discount rate (percent) |  |  |  | 8.00% | 7.50% |  |  |  |
Goodwill impairment, terminal growth rate (percent) |  |  |  | 1.25% | 1.25% |  |  |  |
Goodwill impairment charge |  |  |  | $ 933 | $ 350 |  |  |  |
Other |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |
Goodwill impairment charge |  |  |  |  |  |  | $ 2 | $ 21 |
Other | Rexall Health |  |  |  |  |  |  |  |  |
Goodwill [Line Items] |  |  |  |  |  |  |  |  |
Goodwill impairment, discount rate (percent) |  |  |  | 10.00% |  |  |  |  |
Goodwill impairment, terminal growth rate (percent) |  |  |  | 2.00% |  |  |  |  |
Goodwill impairment charge |  | $ 21 |  | $ 455 |  |  |  |  |

X
- Definition Goodwill, Impaired, Method for Fair Value Determination, Discount Rate + References No definition available. + Details
Name: | mck_GoodwillImpairedMethodforFairValueDeterminationDiscountRate
Namespace Prefix: | mck_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Goodwill, Impaired, Method for Fair Value Determination, Terminal Growth Rate + References No definition available. + Details
Name: | mck_GoodwillImpairedMethodforFairValueDeterminationTerminalGrowthRate
Namespace Prefix: | mck_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266 + Details
Name: | us-gaap_GoodwillImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_GoodwillLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ReportingUnitAxis=mck_MckessonEuropeandRexallReportingUnitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mck_EuropeanPharmaceuticalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=mck_PharmaceuticalDistributionsReportingUnitJune2018OneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=mck_RetailPharmacyReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=mck_PharmaceuticalDistributionsReportingUnitJune2018TwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=mck_PharmaceuticalDistributionsReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=mck_MckessonEuropeReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=mck_RexallHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |